Gilead Sciences Inc. and Pfizer Inc. Announcements: (NASDAQ:GILD), (NYSE:PFE)
Gilead Sciences Inc. (NASDAQ:GILD) announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus (HCV) infection.
View full press release